The Journal of allergy and clinical immunology
-
J. Allergy Clin. Immunol. · Mar 2013
Randomized Controlled TrialThe novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma.
Allergen-specific TH2 responses contribute to the development of allergic asthma. Their increase may be due to a reduced early exposure to environmental pathogens, which induces a TH1 response, and thereby suppresses the allergic TH2 response. QbG10 (bacteriophage Qbeta-derived virus-like particle with CpG-motif G10 inside), a novel Toll-like receptor 9 agonist packaged into virus-like particles, was designed to stimulate the immune system toward a TH1-mediated protective response. ⋯ Treatment with QbG10 may contribute to continued asthma control during steroid reduction in patients on moderate or high-dose inhaled steroids.